Kacital (Potassium Citrate)

After oral administration, potassium citrate dissociates into potassium and citrate ions. The citrate is metabolized to bicarbonate in the liver, raising systemic and urinary pH. This alkalinizing effect increases citrate excretion, which binds calcium and helps prevent stone formation while also correcting low bicarbonate levels in metabolic acidosis.

The specific dose of Kacital is determined by the prescribing healthcare professional based on the individual’s condition, renal function, and laboratory values. Dosage may vary for stone prevention, metabolic acidosis, or urinary alkalinization, and should be followed as directed by the prescriber.

Safety data for potassium citrate in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate the clinical situation before prescribing Kacital to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Kacital. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kacital (potassium citrate) provides both potassium and citrate, offering dual benefits of potassium supplementation and urinary alkalinization. Compared with sodium bicarbonate, it avoids added sodium load, which can be advantageous for patients on sodium‑restricted diets. Its citrate component also directly inhibits calcium stone formation, a feature not shared by all alkalinizing agents.

Kacital should be stored at temperatures below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral formulation.

Kacital is taken orally, usually with a full glass of water. It may be taken with or without food, depending on the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and not exceed the prescribed amount.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and metabolic alkalosis from excessive alkalinization. Patients with impaired renal function or those taking other potassium‑raising medications are at higher risk and should be monitored closely.

Kacital should be avoided in individuals with known hypersensitivity to potassium citrate, severe renal impairment, or existing hyperkalemia. It is also contraindicated in patients taking medications that significantly raise serum potassium unless closely monitored by a healthcare professional.